2 suspended, 1 not yet recruiting, 1 recruiting. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Suspended 2, Not yet recruiting 1, Recruiting 1 |
Follow Tcelltech Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies In Vivo CAR-T Therapy - Relapsed or Refractory Hematologic Malignancies | Phase 1 | Not yet recruiting | Tcelltech Inc. | 15 | 2026-04-15 | 2026-03-20 |
| Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas DIT309 cell injection - Osteosarcoma, Soft Tissue Sarcoma | Phase 1 | Suspended | Tcelltech Inc. | 15 | 2025-11-06 | 2026-10-14 |
| Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 - Solid Tumors | Phase 1 | Suspended | Tcelltech Inc. | 85 | 2025-10-16 | 2026-10-14 |
| Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 - High-grade Glioma, WHO Grade Ⅳ Glioma | Phase 1 | Recruiting | Tcelltech Inc. | 52 | 2024-09-04 | 2026-03-24 |
Glioma (1) · Hematologic Neoplasms (1) · Osteosarcoma (1) · Recurrence (1) · Sarcoma (1)
Immunotherapy, Adoptive (2) · Injections (2)
China (4) · United States (1)